Silence Therapeutics Plc - ADR
SLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$309.71M
Close$
$0.35
98.2% downside
Current Fair Value
98.2% downsideOvervalued by 98.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $309.71 Million |
|---|---|
| Enterprise Value | $237.55 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.67 |
| Beta | 1.42 |
| Outstanding Shares | 15,745,529 |
Return
| Return on Equity | -101.36% |
|---|---|
| Return on Assets | -36.65% |
| Return on Invested Capital | -80.87% |
Valuation & Multiples
| P/E Ratio | -5.16 |
|---|---|
| PEG | 9.36 |
| Price to Sales | - |
| Price to Book Ratio | 9.84 |
| Enterprise Value to Revenue | 386.26 |
| Enterprise Value to EBIT | -3.14 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$1.17 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
$113,400
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0469▼ 161.98% |
|---|---|
| Total Calls | 635,700▲ 3263.49% |
| Total Puts | 29,800▼ 5.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 141.23%▲ 14.78% |
|---|---|
| Total Invested | $238.67M▲ 133.80% |
| Investors Holding | 76▲ 18.00% |
ESG Score
No data
About Silence Therapeutics Plc
74 employees
CEO: David Solomon Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas ...